CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
about
Safety evaluation on low-molecular-weight hydroxyethyl starch for volume expansion therapy in pediatric patients: a meta-analysis of randomized controlled trialsHyperbranched polyglycerol as a colloid in cold organ preservation solutionsYear in review in Intensive Care Medicine 2009: II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching.Year in review in Intensive Care Medicine 2011. II. Cardiovascular, infections, pneumonia and sepsis, critical care organization and outcome, education, ultrasonography, metabolism and coagulationFluid management and risk factors for renal dysfunction in patients with severe sepsis and/or septic shock.Intraoperative fluid management in open gastrointestinal surgery: goal-directed versus restrictiveFormulation and development of plasma volume expander using natural and modified starch from Solanum tuberosum.Cold preservation with hyperbranched polyglycerol-based solution improves kidney functional recovery with less injury at reperfusion in rats.Urinary glutathione S-transferases in the pathogenesis and diagnostic evaluation of acute kidney injury following cardiac surgery: a critical review.Year in review 2009: Critical Care--shock.Low molecular weight pentastarch is more effective than crystalloid solution in goal-directed fluid management in patients undergoing major gastrointestinal surgery.The Bellamy challenge: it's about time.Retrospective cohort study on the incidence of acute kidney injury and death following hydroxyethyl starch (HES 10% 250/0.5/5:1) administration in dogs (2007-2010).Endothelial Glycocalyx and Cardiopulmonary Bypass.[Volume replacement in intensive care medicine].
P2860
Q26991990-92654F1A-D5B1-460D-907B-F903788B712DQ28543625-9AAA094B-D51B-48DB-ADAE-DC8AC41B7E44Q33646147-DDC32C47-5473-4D92-844D-CAA1A55DAD5EQ35795215-6634E652-08C1-4745-975B-9C01E7731932Q36093621-2D2C668E-F299-4B43-92B7-87F38BA6875BQ36284801-CFA95E58-C788-4AB6-9518-3B605BB17415Q37548411-227D5123-672A-4F1A-BE29-129F46B22C26Q37685229-AE10A2A2-DAC3-47B7-B832-64CB6D0D991CQ37798691-A015116D-B88C-4A2E-9335-47F9DDEF3E76Q37814495-EE64D1B8-61DC-4EE4-B9EB-D7C59D53DCE5Q38141896-E0E6AB4A-61F7-4B00-B50B-E5577CD0B7A6Q38154251-BBF9586B-81A4-4F63-B961-5FD5CA511062Q41110540-DCA69831-1660-4775-87AF-880D5173579DQ47695908-FA8D759F-8BC1-452A-BD8D-CA687038E72BQ50162593-2F27BCDF-C44F-40D0-ADB8-2083CEDEFC81
P2860
CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
@en
CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
@nl
type
label
CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
@en
CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
@nl
prefLabel
CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
@en
CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
@nl
P1476
CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.
@en
P2093
Christiane Hartog
Konrad Reinhart
P2860
P2888
P304
P356
10.1007/S00134-009-1521-5
P577
2009-06-17T00:00:00Z